Eliglustat for treating type 1 Gaucher disease

Final evaluation determination

Final evaluation determination document (PDF 556 KB)

Committee papers (PDF 2.56 MB)

Evaluation consultation

Evaluation consultation document (PDF 219 KB)

Evaluation consultation document (PDF 13.27 MB)

Final scope (PDF 101 KB)

Final matrix (PDF 99 KB)

NICE's response to comments on the draft scope and provisional matrix (PDF 409 KB)

Gaucher disease (type 1) - eliglustat: final scope

Gaucher disease (type 1) - eliglustat: final matrix

Gaucher disease (type 1) - eliglustat: NICE's response to consultee and commentator comments on the draft scope and provisional matrix

Gaucher disease (type 1) - eliglustat: appendix B - draft scope for consultation (pre-referral) - November 2013

Gaucher disease (type 1) - eliglustat: appendix C - provisional matrix (pre-referral) - November 2013